Introduction：Basic information about Droloxifene CAS 82413-20-5, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Droloxifene Basic information
| Product Name: | Droloxifene |
| Synonyms: | (E)-3-[1-[4-[2-(DIMETHYLAMINO)ETHOXY]PHENYL]-2-PHENYL-1-BUTENYL]-PHENOL CITRATE;DROLOXIFENE;3-[1-[4-(2-dimethylaminoethoxy)phenyl]-2-phenyl-but-1-enyl]phenol;TAMOXIFEN, 3-HYDROXY-, CITRATE, (E)-;(e)-1-(4’-(2-dimethylaminoethoxy)phenyl)-1-(3’-hydroxyphenyl)-2-phenylbut-1-;(e)-3-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)phenol;(E)-α-[p-[2-(Dimethylamino)ethoxy]phenyl]-β-ethylstilben-3-ol;(E)-3-Hydroxy Tamoxifen |
| CAS: | 82413-20-5 |
| MF: | C26H29NO2 |
| MW: | 387.51 |
| EINECS: | |
| Product Categories: | Drug Analogues;Intermediates & Fine Chemicals;Pharmaceuticals;Aromatics |
| Mol File: | 82413-20-5.mol |
|
Droloxifene Chemical Properties
| Melting point | 127-129°C |
| storage temp. | Amber Vial, -20°C Freezer |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| form | Solid |
| color | White to Pale Beige |
| Stability: | Light Sensitive |
| CAS DataBase Reference | 82413-20-5(CAS DataBase Reference) |
| IARC | 3 (Vol. 66) 1996 |
Safety Information
Droloxifene Usage And Synthesis
| Chemical Properties | Off-White to Pale-Beige Solid |
| Uses | A Tamoxifen derivative with antitumor effect on estrogen-dependent breast cancer cells |
| Uses | A Tamoxifen (T006000) derivative with antitumor effect on estrogen-dependent breast cancer cells. |
| Uses | anti-estrogen, anti-hyperlipoproteinemic, reduces bone loss |
| Definition | ChEBI: Droloxifene is a stilbenoid. |
| in vivo | Droloxifene (5-20 mg/kg; p.o.; daily for 4 weeks) increases BMD of DFM at 10mg/kg, and completely prevents the decrease of BMC and BMD of DFM induced by ovariectomized (OVX) at 20 mg/kg/day[3]. | Animal Model: | 5-month-old sham-operate rats[3] | | Dosage: | 5, 10, 20 mg/kg | | Administration: | Oral; daily for 4 weeks | | Result: | BMD of DFM increased significantly at 10mg/kg; completely prevented the decrease of BMC and BMD of DFM induced by OVX at 20 mg/kg/day. |
|
Droloxifene Preparation Products And Raw materials
